Physician profile
Mark A Esche
NPI 1174622740
$17,558.47
in general payments reported to CMS, 2019-2025
32 companies · $2,739 in 2025
The $2,739 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,955 · 2020: $2,256 · 2021: $2,430 · 2022: $2,182 · 2023: $2,650 · 2024: $2,347 · 2025: $2,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,734 · Education: $1.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,733.79 |
| Education | $1.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,231.88 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $2,044.05 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,891.77 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,819.60 | 2021-2025 | |
| Lundbeck LLC | $1,654.74 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $1,124.72 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,006.25 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $787.19 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $708.70 | 2019-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $637.65 | 2019-2025 | Ingrezza |
| Allergan, INC. | $515.94 | 2019-2020 | |
| Neos Therapeutics, LP | $437.40 | 2019-2024 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $378.59 | 2019-2023 | Spravato |
| Corium, LLC | $369.30 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $353.95 | 2023-2025 | Auvelity, Sunosi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $257.58 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $237.61 | 2019-2021 | |
| Eisai INC. | $176.25 | 2020-2022 | |
| Noven Therapeutics, LLC | $164.84 | 2023-2025 | Xelstrym, Secuado |
| Shire North American Group INC | $152.39 | 2019 | |
| Supernus Pharmaceuticals, INC. | $101.29 | 2022-2023 | Qelbree |
| Adlon Therapeutics L.P. | $100.06 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $95.39 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $78.84 | 2025 | Jornay Pm |
| Tris Pharma INC | $72.27 | 2022-2024 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $44.11 | 2019 | |
| Alfasigma USA, INC. | $31.51 | 2022 | |
| Acadia Pharmaceuticals INC | $27.18 | 2025 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $17.98 | 2025 | Cobenfy |
| Biogen, INC. | $14.24 | 2024 | |
| Rhodes Pharmaceuticals L.P. | $13.52 | 2019 | |
| Merck Sharp & Dohme LLC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Esche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.